Related Experiment Video
Updated: Jul 23, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.4K
Liquid Biopsy: It's the Bloody Truth!
Nathan M Hawkey1, Andrew J Armstrong2
1Division of Hematology and Medical Oncology, Duke University, Durham, North Carolina.
Summary
Liquid biopsy offers vital prognostic information for metastatic castration-resistant prostate cancer. The Foundation Medicine plasma assay shows potential clinical utility for guiding treatment decisions.
Area of Science:
- Oncology
- Molecular Diagnostics
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) requires advanced prognostic tools.
- Liquid biopsy is emerging as a non-invasive method for cancer assessment.
Purpose of the Study:
- To discuss the Foundation Medicine plasma circulating tumor DNA (ctDNA) assay.
- To evaluate its pros, cons, and clinical utility in mCRPC.
Main Methods:
- Review of the Foundation Medicine plasma-based ctDNA assay.
- Analysis of its technical performance and clinical application.
Main Results:
- The plasma ctDNA assay provides critical prognostic information.
- It has potential to inform treatment decisions in mCRPC patients.
Conclusions:
- Liquid biopsy, specifically the Foundation Medicine assay, is a promising tool for mCRPC management.
- Further integration into clinical practice warrants consideration for improved patient outcomes.
